Skip to content

HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function

HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03902366
Enrollment
63
Registered
2019-04-04
Start date
2019-05-16
Completion date
2023-12-29
Last updated
2025-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Use Disorder, Hepatitis C

Keywords

Hepatitis C, Direct-acting antiviral therapies, DAA, Chronic HCV infection, Alcohol Use Disorder

Brief summary

The primary objective of this research project is to compare neuropsychiatric functioning, cortical activity, white matter integrity, and immune response among Veterans with and without alcohol use disorder (AUD), before and after direct-acting antiviral (DAA) therapy \[a new treatment for chronic infection with the hepatitis C virus (HCV)\]. Demographically-matched comparison groups of Veterans without HCV (HCV-, with and without AUD) will similarly be evaluated to determine the relative contribution of HCV and an HCV cure to outcomes putatively affected by alcohol abuse. Two specific aims are proposed. Aim 1: Determine the impact of DAA therapy and a sustained viral response on central nervous system (CNS) function. Aim 2: Evaluate the effects of AUD and unhealthy alcohol drinking on DAA therapy outcomes and CNS function. The information learned will address a critical gap in knowledge concerning the effects of alcohol use on DAA therapy outcomes and will help inform treatment guidelines that could be translated to clinical practice, such as targeted interventions to treat AUD in conjunction with HCV infection and follow-up strategies for patients who successfully complete DAA therapy but then need care for other potential CNS-related outcomes.

Detailed description

Aim 1 will evaluate the impact of DAA therapy on CNS function in Veterans with HCV and will test the hypotheses that following DAA therapy and obtaining a sustained viral response (SVR) \[i.e., when the virus continues to be undetectable in blood 12 weeks (or more) after completing therapy\], participants will show: i) improved neuropsychiatric outcomes (e.g., cognitive function, fatigue, mood), as compared to baseline (pre-DAA therapy), ii) restored functional connectivity and structural integrity within white matter tracks that had been observed at baseline, and iii) reduced immune activation profiles (e.g., decreased expression of inflammatory biomarkers and restored T cell balance), as compared to baseline. Aim 2 will determine the impact of an active AUD on the neuropsychiatric, neuroimaging, and immunological outcomes observed in aim 1. Participants will be evaluated at two time points \[i.e., baseline and 12 weeks post-therapy (week 24)\]. Evaluations will incorporate brain imaging methods \[i.e., resting state magnetic resonance imaging (MRI), functional MRI, and diffusion tensor imaging\] along with clinical and laboratory methods to assess the interactive effects of alcohol use and HCV on brain function. Clinical and laboratory data will include: i) demographic and medical information, ii) neuropsychological measures of attention, memory, and executive function, iii) neuropsychiatric symptom questionnaires (e.g., depression and anxiety), iv) urine and oral fluid collection for medical laboratory tests, and v) blood sample collection for planned experiments (e.g., flow cytometry, quantitative polymerase chain reaction (qPCR), and multiplex immunoassays) and for contribution to the VA Liver Disease Repository. Evidence-based guidelines for the new DAA therapies are needed (e.g., How much alcohol is too much?). The VA is at the forefront of treating HCV and is now offering DAA therapy to all Veterans with HCV treated within VA health care systems. The proposed studies will address a critical gap in our knowledge concerning the effects of co-morbid HCV and AUD on antiviral therapy outcomes, particularly CNS function and neuropsychiatric symptoms that contribute to addiction and relapse.

Interventions

DIAGNOSTIC_TESTNeuropsychological assessment

Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).

BEHAVIORALNeuroimaging

Subjects, well characterized with respect to their substance use, will be evaluated with functional magnetic resonance imaging (fMRI) tasks, resting state MRI (rsMRI), high resolution anatomical MRI, standard diffusion weighted imaging (DWI) and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.

Sponsors

Oregon Health and Science University
CollaboratorOTHER
Portland VA Medical Center
CollaboratorFED
VA Office of Research and Development
Lead SponsorFED

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult Veteran (\>21 years) * Able to provide informed consent.

Exclusion criteria

* Current substance use disorder other than alcohol (except nicotine or caffeine) * Medical conditions likely to impact immunological function or central nervous system function (such as HIV, cancer, lupus, stroke, neurodegenerative disease, hepatic encephalopathy, multiple sclerosis, or a traumatic brain injury) * Visible intoxication or impaired capacity to understand study risks and benefits or otherwise provide informed consent * Past or present schizophrenia, schizoaffective disorder, or current psychosis or mania * Visual or auditory impairments that would prevent valid neuropsychiatric testing * Contraindications to MRI (such as surgical aneurysm clips, pacemaker, prosthetic heart valve, neuro-stimulator, implanted pumps, cochlear implants, metal rods, plates or screws, previous surgery, hearing aids, history of welding, metal shrapnel)

Design outcomes

Primary

MeasureTime frameDescription
Changes in Neuropsychological Assessment Battery (NAB) Attention Module ScoresBaseline and 6 monthsThe Attention Module is a marker of attentional capacity, working memory, and processing speed. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Attention Module subtests include: Dots, Numbers and Letters, Driving Scenes, Digits Forward, and Digits Backward. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in attention performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of attention performance over time.
Changes in Neuropsychological Assessment Battery (NAB) Memory Module ScoresBaseline and 6 monthsThe Memory Module is a marker of learning, recall, and recognition memory. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Memory Module subtests include: List Learning, Shape Learning, Story Learning, and Daily Living Memory. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in memory performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of memory performance over time.
Changes in Neuropsychological Assessment Battery (NAB) Executive Functions Module ScoresBaseline and 6 monthsThe Executive Functions Module of the NAB is a marker of executive function, including problem-solving and mental flexibility. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Executive Function Module subtests include: Mazes, Judgement, Categories, and Word Generation. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in executive function performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of executive functioning performance over time.
Changes in Alcohol Use Measured Using the Timeline Follow Back (TLFB)Baseline and 6 monthsThis outcome measure evaluates the change in the number of days of alcohol use from baseline to a 6-month follow-up, using the 30-Day Timeline Followback (TLFB) method. The TLFB is a structured, retrospective interview technique that allows participants to accurately recall their alcohol consumption patterns over the previous 30 days. For this outcome, the number of days on which alcohol was consumed will be assessed at baseline (the start of the study) and again at the 6-month follow-up assessment. A positive change would indicate an increase in the number of days of alcohol use, while a negative change would indicate a reduction in the number of days of alcohol use over the 6-month period.
Change in Behavior as Assessed by the Balloon Analogue Risk Task (BART)Baseline and 6 monthsThe BART is a computerized measure of risk-taking behavior that concurrently measures several domains (i.e., risky decision-making, reward/negative outcome processing) during fMRI scanning. The ratio of balloon pumps made to maximum pumps allowed is a measure of risk-taking behavior. A ratio of 1 indicates that a participant inflated the balloon to its maximum allowed pumps, while a ratio closer to 0 suggests that the participant was much more conservative in their approach. Change was calculated as the value at 6 months minus the value at baseline and ranges from -1 to 1. A positive change indicates an increase in risk-taking behavior and a negative change indicates a decrease in risk-taking behavior over time.
Change in Behavior as Assessed by the Monetary Incentive Delay (MID) TaskBaseline and 6 monthsThe MID is a validated task to examine anticipatory brain responses to reward during fMRI scanning. This outcome measure evaluates the change in reaction time (RT) of participants in response to monetary reward cues during the MID. Reaction time is defined as the duration (in milliseconds) from the presentation of the cue to the participant's response (e.g., button press). The MID involves various reward conditions, including different monetary values and probabilities, allowing for an evaluation of participants' anticipatory responses to potential rewards. A positive difference indicates an increase in RT at 6-months compared to baseline, suggesting potential decreases in motivation, cognitive load, or changes in reward sensitivity. Conversely, a negative difference indicates a decrease in reaction time, which may reflect improved motivation, enhanced cognitive processing speed, or increased responsiveness to monetary incentives over time.
Change in Fatigue Severity Scale (FSS) ScoreBaseline and 6 monthsThe Fatigue Severity Scale (FSS) is a 9-item self-report questionnaire designed to measure level of fatigue. The FSS is graded on a 7-point Likert-like scale ranging from 1 (strongly disagree) to 7 (strongly agree). The score for all 9 items is summed to constitute the FSS score. The minimum FSS score is 7 and the maximum score possible is 63. A higher score represents greater fatigue severity. Change was calculated as the value at 6 months minus the value at baseline and reported here. A higher positive score indicates an increase in fatigue symptoms at 6 months compared to baseline, a lower negative score would indicate a decrease in fatigue symptoms over 6 months and a score of 0 would indicate no change in fatigue symptoms over 6 months.
Change in Beck Depression Inventory Second Edition (BDI-II) ScoreBaseline and 6 monthsThe Beck Depression Inventory Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory that measures depression. There is a four-point scale for each item ranging from 0-3. The total score can range from 0 to 63 points. Higher scores reflect a great level of depression severity.
Change in Fractional Anisotropy (FA) in White Matter TractsBaseline and 6 monthsMRI-based diffusion tensor imaging (DTI) tractography is used to measure fractional anisotropy (FA), an indicator of CNS microstructural integrity. Increases in FA may reflect enhanced fiber organization or myelination, while decreases often indicate demyelination, axonal loss, or reduced coherence of white matter tracts. The JHU white-matter tractography atlas was used to extract FA values from 20 structures. Percent change was calculated. A positive number indicates an increase in FA after 6 months and a negative number indicates a decrease in FA from baseline to 6 months.
Change in Mean Diffusivity (MD) in White Matter TractsBaseline and 6 monthsMRI-based diffusion tensor imaging (DTI) tractography is used to measure mean diffusivity (MD), which is the average rate of water diffusion in all directions within brain tissue. An increase in MD often indicates microstructural disruption, such as axonal loss, demyelination, or increased extracellular space due to edema or atrophy and decreases in MD can reflect cellular proliferation or restricted diffusion, as seen in certain types of gliosis or inflammatory conditions. The JHU white-matter tractography atlas was used to extract MD values from 20 structures. Percent change was calculated. A positive number indicates an increase in MD after 6 months and a negative number indicates a decrease in MD from baseline to 6 months.
Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR)Baseline and 6 monthsChange was calculated as the value at 6 months minus the value and baseline. A positive number indicates an increase in inflammatory markers in plasma samples and a negative value indicates a decrease in inflammatory markers at 6 months.

Countries

United States

Participant flow

Pre-assignment details

Of 119 assessed for eligibility, 63 met inclusion criteria (38 AUD-/HCV-, 20 AUD+/HCV-, 5 HCVc) and were enrolled in the study. 17 participants were excluded after enrollment. Due to low recruitment numbers and no significant differences between the HCV groups, individuals with a history of HCV were assigned to one group (HCVc).

Participants by arm

ArmCount
Control (AUD-)
-Without Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
27
Alcohol Use Disorder (AUD+)
-With Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
14
HCVc
-Adults treated for HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
5
Total46

Baseline characteristics

CharacteristicControl (AUD-)TotalHCVcAlcohol Use Disorder (AUD+)
Age, Continuous53.70 years
STANDARD_DEVIATION 14.87
56.59 years
STANDARD_DEVIATION 14.1
63.40 years
STANDARD_DEVIATION 5.37
59.71 years
STANDARD_DEVIATION 13.84
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants3 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
24 Participants43 Participants5 Participants14 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
2 Participants3 Participants1 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants1 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
5 Participants8 Participants1 Participants2 Participants
Race (NIH/OMB)
More than one race
3 Participants3 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
16 Participants31 Participants3 Participants12 Participants
Region of Enrollment
United States
27 Participants46 Participants5 Participants14 Participants
Sex: Female, Male
Female
9 Participants14 Participants1 Participants4 Participants
Sex: Female, Male
Male
18 Participants32 Participants4 Participants10 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 270 / 140 / 5
other
Total, other adverse events
0 / 270 / 140 / 5
serious
Total, serious adverse events
0 / 270 / 140 / 5

Outcome results

Primary

Change in Beck Depression Inventory Second Edition (BDI-II) Score

The Beck Depression Inventory Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory that measures depression. There is a four-point scale for each item ranging from 0-3. The total score can range from 0 to 63 points. Higher scores reflect a great level of depression severity.

Time frame: Baseline and 6 months

ArmMeasureValue (MEAN)Dispersion
Control (AUD-)Change in Beck Depression Inventory Second Edition (BDI-II) Score2.48 score on a scaleStandard Deviation 5.98
Alcohol Use Disorder (AUD+)Change in Beck Depression Inventory Second Edition (BDI-II) Score1.92 score on a scaleStandard Deviation 7.39
HCVcChange in Beck Depression Inventory Second Edition (BDI-II) Score-0.60 score on a scaleStandard Deviation 4.83
Primary

Change in Behavior as Assessed by the Balloon Analogue Risk Task (BART)

The BART is a computerized measure of risk-taking behavior that concurrently measures several domains (i.e., risky decision-making, reward/negative outcome processing) during fMRI scanning. The ratio of balloon pumps made to maximum pumps allowed is a measure of risk-taking behavior. A ratio of 1 indicates that a participant inflated the balloon to its maximum allowed pumps, while a ratio closer to 0 suggests that the participant was much more conservative in their approach. Change was calculated as the value at 6 months minus the value at baseline and ranges from -1 to 1. A positive change indicates an increase in risk-taking behavior and a negative change indicates a decrease in risk-taking behavior over time.

Time frame: Baseline and 6 months

Population: Only 28 of the 46 participants that completed the study, completed both imaging sessions (baseline and 6 months) and were considered for further imaging analyses. Of the 28 participants, one control participant and one participant with cleared HCV (HCVc) were not included in the analysis because task data from at least one timepoint was not collected.

ArmMeasureValue (MEAN)Dispersion
Control (AUD-)Change in Behavior as Assessed by the Balloon Analogue Risk Task (BART)-0.018 ratioStandard Deviation 0.093
Alcohol Use Disorder (AUD+)Change in Behavior as Assessed by the Balloon Analogue Risk Task (BART)-0.005 ratioStandard Deviation 0.079
HCVcChange in Behavior as Assessed by the Balloon Analogue Risk Task (BART)-0.014 ratioStandard Deviation 0.164
Primary

Change in Behavior as Assessed by the Monetary Incentive Delay (MID) Task

The MID is a validated task to examine anticipatory brain responses to reward during fMRI scanning. This outcome measure evaluates the change in reaction time (RT) of participants in response to monetary reward cues during the MID. Reaction time is defined as the duration (in milliseconds) from the presentation of the cue to the participant's response (e.g., button press). The MID involves various reward conditions, including different monetary values and probabilities, allowing for an evaluation of participants' anticipatory responses to potential rewards. A positive difference indicates an increase in RT at 6-months compared to baseline, suggesting potential decreases in motivation, cognitive load, or changes in reward sensitivity. Conversely, a negative difference indicates a decrease in reaction time, which may reflect improved motivation, enhanced cognitive processing speed, or increased responsiveness to monetary incentives over time.

Time frame: Baseline and 6 months

Population: Only 28 of the 46 participants that completed the study, completed both imaging sessions (baseline and 6 months) and were considered for further imaging analyses. Of the 28 participants, two participants (1 HCVc, 1 AUD) were excluded from the study for having incomplete task data.

ArmMeasureValue (MEAN)Dispersion
Control (AUD-)Change in Behavior as Assessed by the Monetary Incentive Delay (MID) Task-0.39 millisecondsStandard Deviation 22.83
Alcohol Use Disorder (AUD+)Change in Behavior as Assessed by the Monetary Incentive Delay (MID) Task12.77 millisecondsStandard Deviation 19.78
HCVcChange in Behavior as Assessed by the Monetary Incentive Delay (MID) Task3.63 millisecondsStandard Deviation 14.17
Primary

Change in Fatigue Severity Scale (FSS) Score

The Fatigue Severity Scale (FSS) is a 9-item self-report questionnaire designed to measure level of fatigue. The FSS is graded on a 7-point Likert-like scale ranging from 1 (strongly disagree) to 7 (strongly agree). The score for all 9 items is summed to constitute the FSS score. The minimum FSS score is 7 and the maximum score possible is 63. A higher score represents greater fatigue severity. Change was calculated as the value at 6 months minus the value at baseline and reported here. A higher positive score indicates an increase in fatigue symptoms at 6 months compared to baseline, a lower negative score would indicate a decrease in fatigue symptoms over 6 months and a score of 0 would indicate no change in fatigue symptoms over 6 months.

Time frame: Baseline and 6 months

ArmMeasureValue (MEAN)Dispersion
Control (AUD-)Change in Fatigue Severity Scale (FSS) Score4.87 score on a scaleStandard Deviation 12.95
Alcohol Use Disorder (AUD+)Change in Fatigue Severity Scale (FSS) Score2.46 score on a scaleStandard Deviation 15.05
HCVcChange in Fatigue Severity Scale (FSS) Score4.80 score on a scaleStandard Deviation 11.97
Primary

Change in Fractional Anisotropy (FA) in White Matter Tracts

MRI-based diffusion tensor imaging (DTI) tractography is used to measure fractional anisotropy (FA), an indicator of CNS microstructural integrity. Increases in FA may reflect enhanced fiber organization or myelination, while decreases often indicate demyelination, axonal loss, or reduced coherence of white matter tracts. The JHU white-matter tractography atlas was used to extract FA values from 20 structures. Percent change was calculated. A positive number indicates an increase in FA after 6 months and a negative number indicates a decrease in FA from baseline to 6 months.

Time frame: Baseline and 6 months

Population: Only 28 of the 46 participants that completed the study, completed both imaging sessions (baseline and 6 months) and were considered for further imaging analyses. Of the 28 participants, 4 participants (1 Control, 1 AUD, and 2 HCVc) were not included in the analysis because they had missing or corrupted imaging files.

ArmMeasureGroupValue (MEAN)Dispersion
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Superior longitudinal fasciculus, temporal part0.540 percent changeStandard Deviation 1.543
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Inferior longitudinal fasciculus0.474 percent changeStandard Deviation 1.764
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsRight Anterior thalamic radiation0.297 percent changeStandard Deviation 2.158
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsRight Superior longitudinal fasciculus, temporal part-0.017 percent changeStandard Deviation 1.474
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsForceps major0.400 percent changeStandard Deviation 2.038
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Cingulum hippocampus1.168 percent changeStandard Deviation 3.19
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Uncinate fasciculus0.462 percent changeStandard Deviation 3.711
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Corticospinal tract0.337 percent changeStandard Deviation 1.045
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Anterior thalamic radiation0.416 percent changeStandard Deviation 1.791
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsRight Uncinate fasciculus-0.409 percent changeStandard Deviation 3.708
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsRight Cingulum hippocampus-0.113 percent changeStandard Deviation 1.969
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Superior longitudinal fasciculus0.424 percent changeStandard Deviation 1.429
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsRight Inferior fronto-occipital fasciculus0.014 percent changeStandard Deviation 2.693
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsRight Cingulum cingulate gyrus0.340 percent changeStandard Deviation 1.557
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsRight Superior longitudinal fasciculus-0.284 percent changeStandard Deviation 1.76
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsForceps minor0.317 percent changeStandard Deviation 3.4
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Cingulum cingulate gyrus0.341 percent changeStandard Deviation 2.384
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Inferior fronto-occipital fasciculus0.542 percent changeStandard Deviation 2.558
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsRight Inferior longitudinal fasciculus0.017 percent changeStandard Deviation 1.971
Control (AUD-)Change in Fractional Anisotropy (FA) in White Matter TractsRight Corticospinal tract0.130 percent changeStandard Deviation 1.32
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsRight Cingulum cingulate gyrus-0.095 percent changeStandard Deviation 2.21
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Inferior fronto-occipital fasciculus0.005 percent changeStandard Deviation 2.503
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsRight Inferior fronto-occipital fasciculus-0.410 percent changeStandard Deviation 1.772
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Inferior longitudinal fasciculus-0.002 percent changeStandard Deviation 1.995
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Superior longitudinal fasciculus-0.027 percent changeStandard Deviation 1.492
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsRight Superior longitudinal fasciculus-0.548 percent changeStandard Deviation 1.26
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsRight Inferior longitudinal fasciculus-0.234 percent changeStandard Deviation 1.834
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Superior longitudinal fasciculus, temporal part-0.158 percent changeStandard Deviation 1.484
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsRight Superior longitudinal fasciculus, temporal part-0.671 percent changeStandard Deviation 1.173
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Uncinate fasciculus0.341 percent changeStandard Deviation 3.566
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsRight Uncinate fasciculus-1.324 percent changeStandard Deviation 2.321
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Anterior thalamic radiation-0.612 percent changeStandard Deviation 2.045
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Cingulum hippocampus0.259 percent changeStandard Deviation 2.576
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsRight Anterior thalamic radiation-0.768 percent changeStandard Deviation 1.85
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Cingulum cingulate gyrus-0.231 percent changeStandard Deviation 2.41
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsForceps minor-0.805 percent changeStandard Deviation 2.628
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsRight Cingulum hippocampus-0.612 percent changeStandard Deviation 2.508
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsLeft Corticospinal tract-0.522 percent changeStandard Deviation 1.402
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsRight Corticospinal tract-0.166 percent changeStandard Deviation 1.641
Alcohol Use Disorder (AUD+)Change in Fractional Anisotropy (FA) in White Matter TractsForceps major-0.295 percent changeStandard Deviation 2.426
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsRight Anterior thalamic radiation-1.189 percent changeStandard Deviation 1.125
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsRight Superior longitudinal fasciculus-1.840 percent changeStandard Deviation 0.379
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsForceps major-2.476 percent changeStandard Deviation 0.821
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsLeft Cingulum cingulate gyrus-2.038 percent changeStandard Deviation 0.731
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsLeft Superior longitudinal fasciculus-1.035 percent changeStandard Deviation 0.744
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsRight Corticospinal tract-2.396 percent changeStandard Deviation 0.712
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsRight Cingulum cingulate gyrus-1.218 percent changeStandard Deviation 0.224
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsRight Inferior longitudinal fasciculus-2.245 percent changeStandard Deviation 1.131
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsLeft Inferior fronto-occipital fasciculus-1.700 percent changeStandard Deviation 0.534
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsRight Cingulum hippocampus-2.015 percent changeStandard Deviation 3.444
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsLeft Inferior longitudinal fasciculus-1.790 percent changeStandard Deviation 0.358
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsRight Uncinate fasciculus-1.609 percent changeStandard Deviation 1.299
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsLeft Uncinate fasciculus-1.277 percent changeStandard Deviation 0.614
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsForceps minor-0.986 percent changeStandard Deviation 1.692
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsRight Superior longitudinal fasciculus, temporal part-1.525 percent changeStandard Deviation 0.144
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsLeft Corticospinal tract-1.271 percent changeStandard Deviation 0.737
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsLeft Cingulum hippocampus-2.062 percent changeStandard Deviation 0.461
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsLeft Anterior thalamic radiation-1.953 percent changeStandard Deviation 0.888
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsLeft Superior longitudinal fasciculus, temporal part-1.363 percent changeStandard Deviation 0.398
HCVcChange in Fractional Anisotropy (FA) in White Matter TractsRight Inferior fronto-occipital fasciculus-1.756 percent changeStandard Deviation 0.072
Primary

Change in Mean Diffusivity (MD) in White Matter Tracts

MRI-based diffusion tensor imaging (DTI) tractography is used to measure mean diffusivity (MD), which is the average rate of water diffusion in all directions within brain tissue. An increase in MD often indicates microstructural disruption, such as axonal loss, demyelination, or increased extracellular space due to edema or atrophy and decreases in MD can reflect cellular proliferation or restricted diffusion, as seen in certain types of gliosis or inflammatory conditions. The JHU white-matter tractography atlas was used to extract MD values from 20 structures. Percent change was calculated. A positive number indicates an increase in MD after 6 months and a negative number indicates a decrease in MD from baseline to 6 months.

Time frame: Baseline and 6 months

Population: Only 28 of the 46 participants that completed the study, completed both imaging sessions (baseline and 6 months) and were considered for further imaging analyses. Of the 28 participants, 4 participants (1 Control, 1 AUD, and 2 HCVc) were not included in the analysis because they had missing or corrupted imaging files.

ArmMeasureGroupValue (MEAN)Dispersion
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsLeft Anterior thalamic radiation-0.740 percent changeStandard Deviation 1.039
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsRight Anterior thalamic radiation-0.827 percent changeStandard Deviation 0.993
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsLeft Superior longitudinal fasciculus, temporal part-0.892 percent changeStandard Deviation 1.243
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsLeft Corticospinal tract-0.372 percent changeStandard Deviation 0.985
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsRight Superior longitudinal fasciculus-0.615 percent changeStandard Deviation 1.116
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsLeft Inferior fronto-occipital fasciculus-1.191 percent changeStandard Deviation 1.161
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsRight Cingulum cingulate gyrus-0.919 percent changeStandard Deviation 1.566
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsLeft Superior longitudinal fasciculus-0.806 percent changeStandard Deviation 1.237
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsRight Inferior fronto-occipital fasciculus-0.862 percent changeStandard Deviation 1.155
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsRight Uncinate fasciculus-0.864 percent changeStandard Deviation 1.716
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsRight Inferior longitudinal fasciculus-1.006 percent changeStandard Deviation 1.231
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsLeft Inferior longitudinal fasciculus-1.128 percent changeStandard Deviation 1.374
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsRight Corticospinal tract-0.359 percent changeStandard Deviation 0.701
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsLeft Cingulum cingulate gyrus-0.835 percent changeStandard Deviation 1.458
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsLeft Uncinate fasciculus-1.367 percent changeStandard Deviation 1.541
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsForceps major-0.474 percent changeStandard Deviation 1.542
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsRight Cingulum hippocampus-0.797 percent changeStandard Deviation 1.66
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsRight Superior longitudinal fasciculus, temporal part-0.777 percent changeStandard Deviation 1.093
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsForceps minor-0.832 percent changeStandard Deviation 1.471
Control (AUD-)Change in Mean Diffusivity (MD) in White Matter TractsLeft Cingulum hippocampus-0.932 percent changeStandard Deviation 2.626
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsRight Uncinate fasciculus0.582 percent changeStandard Deviation 2.398
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsRight Cingulum cingulate gyrus-0.177 percent changeStandard Deviation 2.08
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsLeft Cingulum hippocampus0.099 percent changeStandard Deviation 3.176
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsRight Cingulum hippocampus0.015 percent changeStandard Deviation 2.18
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsLeft Corticospinal tract0.811 percent changeStandard Deviation 1.18
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsRight Corticospinal tract0.029 percent changeStandard Deviation 0.928
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsForceps major0.756 percent changeStandard Deviation 1.905
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsLeft Uncinate fasciculus-0.334 percent changeStandard Deviation 1.792
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsLeft Anterior thalamic radiation0.490 percent changeStandard Deviation 1.129
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsForceps minor0.302 percent changeStandard Deviation 2.164
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsLeft Inferior fronto-occipital fasciculus-0.014 percent changeStandard Deviation 1.291
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsRight Inferior fronto-occipital fasciculus0.276 percent changeStandard Deviation 1.685
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsLeft Inferior longitudinal fasciculus0.325 percent changeStandard Deviation 1.185
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsRight Inferior longitudinal fasciculus0.082 percent changeStandard Deviation 1.67
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsLeft Superior longitudinal fasciculus0.293 percent changeStandard Deviation 1.154
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsRight Superior longitudinal fasciculus0.276 percent changeStandard Deviation 1.532
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsLeft Superior longitudinal fasciculus, temporal part0.370 percent changeStandard Deviation 1.109
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsRight Superior longitudinal fasciculus, temporal part0.284 percent changeStandard Deviation 1.34
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsLeft Cingulum cingulate gyrus0.453 percent changeStandard Deviation 1.269
Alcohol Use Disorder (AUD+)Change in Mean Diffusivity (MD) in White Matter TractsRight Anterior thalamic radiation0.358 percent changeStandard Deviation 1.662
HCVcChange in Mean Diffusivity (MD) in White Matter TractsForceps minor-0.674 percent changeStandard Deviation 1.426
HCVcChange in Mean Diffusivity (MD) in White Matter TractsRight Cingulum cingulate gyrus0.521 percent changeStandard Deviation 0.847
HCVcChange in Mean Diffusivity (MD) in White Matter TractsRight Superior longitudinal fasciculus0.724 percent changeStandard Deviation 1.051
HCVcChange in Mean Diffusivity (MD) in White Matter TractsLeft Anterior thalamic radiation0.159 percent changeStandard Deviation 1.507
HCVcChange in Mean Diffusivity (MD) in White Matter TractsRight Anterior thalamic radiation0.393 percent changeStandard Deviation 1.856
HCVcChange in Mean Diffusivity (MD) in White Matter TractsLeft Superior longitudinal fasciculus, temporal part0.516 percent changeStandard Deviation 0.272
HCVcChange in Mean Diffusivity (MD) in White Matter TractsForceps major1.771 percent changeStandard Deviation 0.407
HCVcChange in Mean Diffusivity (MD) in White Matter TractsLeft Cingulum hippocampus2.535 percent changeStandard Deviation 1.258
HCVcChange in Mean Diffusivity (MD) in White Matter TractsRight Superior longitudinal fasciculus, temporal part0.282 percent changeStandard Deviation 0.952
HCVcChange in Mean Diffusivity (MD) in White Matter TractsRight Corticospinal tract1.169 percent changeStandard Deviation 1.674
HCVcChange in Mean Diffusivity (MD) in White Matter TractsLeft Uncinate fasciculus-0.633 percent changeStandard Deviation 0.121
HCVcChange in Mean Diffusivity (MD) in White Matter TractsLeft Corticospinal tract0.522 percent changeStandard Deviation 0.881
HCVcChange in Mean Diffusivity (MD) in White Matter TractsLeft Cingulum cingulate gyrus-0.288 percent changeStandard Deviation 1.983
HCVcChange in Mean Diffusivity (MD) in White Matter TractsLeft Inferior longitudinal fasciculus1.089 percent changeStandard Deviation 0.099
HCVcChange in Mean Diffusivity (MD) in White Matter TractsRight Inferior fronto-occipital fasciculus0.861 percent changeStandard Deviation 1.655
HCVcChange in Mean Diffusivity (MD) in White Matter TractsRight Uncinate fasciculus0.586 percent changeStandard Deviation 1.752
HCVcChange in Mean Diffusivity (MD) in White Matter TractsRight Inferior longitudinal fasciculus1.095 percent changeStandard Deviation 0.914
HCVcChange in Mean Diffusivity (MD) in White Matter TractsLeft Inferior fronto-occipital fasciculus0.240 percent changeStandard Deviation 0.238
HCVcChange in Mean Diffusivity (MD) in White Matter TractsRight Cingulum hippocampus1.131 percent changeStandard Deviation 4.55
HCVcChange in Mean Diffusivity (MD) in White Matter TractsLeft Superior longitudinal fasciculus0.249 percent changeStandard Deviation 0.342
Primary

Changes in Alcohol Use Measured Using the Timeline Follow Back (TLFB)

This outcome measure evaluates the change in the number of days of alcohol use from baseline to a 6-month follow-up, using the 30-Day Timeline Followback (TLFB) method. The TLFB is a structured, retrospective interview technique that allows participants to accurately recall their alcohol consumption patterns over the previous 30 days. For this outcome, the number of days on which alcohol was consumed will be assessed at baseline (the start of the study) and again at the 6-month follow-up assessment. A positive change would indicate an increase in the number of days of alcohol use, while a negative change would indicate a reduction in the number of days of alcohol use over the 6-month period.

Time frame: Baseline and 6 months

ArmMeasureValue (MEAN)Dispersion
Control (AUD-)Changes in Alcohol Use Measured Using the Timeline Follow Back (TLFB)3.78 change in the number of days of alcoholStandard Deviation 9.69
Alcohol Use Disorder (AUD+)Changes in Alcohol Use Measured Using the Timeline Follow Back (TLFB)44.00 change in the number of days of alcoholStandard Deviation 81.85
HCVcChanges in Alcohol Use Measured Using the Timeline Follow Back (TLFB)-6.25 change in the number of days of alcoholStandard Deviation 12.5
Primary

Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR)

Change was calculated as the value at 6 months minus the value and baseline. A positive number indicates an increase in inflammatory markers in plasma samples and a negative value indicates a decrease in inflammatory markers at 6 months.

Time frame: Baseline and 6 months

ArmMeasureGroupValue (MEAN)Dispersion
Control (AUD-)Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR)NLR-0.36 cell count x 10^3/uL [ratio]Standard Deviation 0.58
Control (AUD-)Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR)MLR-0.03 cell count x 10^3/uL [ratio]Standard Deviation 0.07
Alcohol Use Disorder (AUD+)Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR)NLR0.17 cell count x 10^3/uL [ratio]Standard Deviation 0.52
Alcohol Use Disorder (AUD+)Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR)MLR0.03 cell count x 10^3/uL [ratio]Standard Deviation 0.07
HCVcChanges in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR)NLR-0.50 cell count x 10^3/uL [ratio]Standard Deviation 0.42
HCVcChanges in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR)MLR0.45 cell count x 10^3/uL [ratio]Standard Deviation 0.7
Primary

Changes in Neuropsychological Assessment Battery (NAB) Attention Module Scores

The Attention Module is a marker of attentional capacity, working memory, and processing speed. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Attention Module subtests include: Dots, Numbers and Letters, Driving Scenes, Digits Forward, and Digits Backward. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in attention performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of attention performance over time.

Time frame: Baseline and 6 months

ArmMeasureValue (MEAN)Dispersion
Control (AUD-)Changes in Neuropsychological Assessment Battery (NAB) Attention Module Scores10.99 Units on a scaleStandard Deviation 3.37
Alcohol Use Disorder (AUD+)Changes in Neuropsychological Assessment Battery (NAB) Attention Module Scores0.31 Units on a scaleStandard Deviation 1.18
HCVcChanges in Neuropsychological Assessment Battery (NAB) Attention Module Scores6.35 Units on a scaleStandard Deviation 5.92
Primary

Changes in Neuropsychological Assessment Battery (NAB) Executive Functions Module Scores

The Executive Functions Module of the NAB is a marker of executive function, including problem-solving and mental flexibility. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Executive Function Module subtests include: Mazes, Judgement, Categories, and Word Generation. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in executive function performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of executive functioning performance over time.

Time frame: Baseline and 6 months

ArmMeasureValue (MEAN)Dispersion
Control (AUD-)Changes in Neuropsychological Assessment Battery (NAB) Executive Functions Module Scores10.65 Units on a scaleStandard Deviation 0.25
Alcohol Use Disorder (AUD+)Changes in Neuropsychological Assessment Battery (NAB) Executive Functions Module Scores5.46 Units on a scaleStandard Deviation 1.01
HCVcChanges in Neuropsychological Assessment Battery (NAB) Executive Functions Module Scores18.00 Units on a scaleStandard Deviation 14.14
Primary

Changes in Neuropsychological Assessment Battery (NAB) Memory Module Scores

The Memory Module is a marker of learning, recall, and recognition memory. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Memory Module subtests include: List Learning, Shape Learning, Story Learning, and Daily Living Memory. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in memory performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of memory performance over time.

Time frame: Baseline and 6 months

ArmMeasureValue (MEAN)Dispersion
Control (AUD-)Changes in Neuropsychological Assessment Battery (NAB) Memory Module Scores9.07 Units on a scaleStandard Deviation 1.12
Alcohol Use Disorder (AUD+)Changes in Neuropsychological Assessment Battery (NAB) Memory Module Scores1.95 Units on a scaleStandard Deviation 1.52
HCVcChanges in Neuropsychological Assessment Battery (NAB) Memory Module Scores3.50 Units on a scaleStandard Deviation 0.71

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026